Key facts
- It has raised $5.0M across 2 recorded rounds; the latest was Seed Round ($1.2M) in Jun 2026.
- Notable investors include US National Science Foundation, BioGenerator Ventures, Bio Research & Development Growth Park, Danforth Technology Company, Helix Funds — 7 tracked in total.
- Spearhead Bio has filed 1 Form D with the SEC, most recently Feb 2025 ($1.0M sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Spearhead Bio
Funding rounds
2 roundsAbout Spearhead Bio
Developer of a native genome engineering platform designed to enhance the efficiency of crop genome engineering. The company's platform offers tools to significantly enhance the efficiency of crop genome engineering using the plant's natural DNA while ensuring seamless integration, reducing regulatory hurdles, and increasing consumer acceptance, enabling breeders and researchers to improve crop performance, sustainability, and food security while reducing regulatory hurdles and increasing consumer acceptance.
- Sector
- Healthcare
- HQ
- Saint Louis, MO, United States
- Founded
- 2025
- Employees
- 3
- Website
- spearheadbio.com/
- Ownership
- Privately Held (backing)
Spearhead Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Spearhead Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Spearhead Bio in its N-PORT filings yet. We sweep new filings monthly.